Cargando…

(Immuno)proteasomes as therapeutic target in acute leukemia

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has encouraged application of proteasome inhibitor containing therapeutic interventions in (pediatric) acute leukemia. Here, we summarize the positioning of bortezomib, as first-generation proteasome inhibitor, and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cloos, Jacqueline, Roeten, Margot SF, Franke, Niels E, van Meerloo, Johan, Zweegman, Sonja, Kaspers, Gertjan JL, Jansen, Gerrit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721123/ https://www.ncbi.nlm.nih.gov/pubmed/29071527 http://dx.doi.org/10.1007/s10555-017-9699-4

Ejemplares similares

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

Positioning of proteasome inhibitors in therapy of solid malignancies
por: Roeten, Margot S. F., et al.
Publicado: (2017)

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors
por: Franke, Niels E., et al.
Publicado: (2016)

Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy
por: Niewerth, Denise, et al.
Publicado: (2016)

Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines
por: Niewerth, Denise, et al.
Publicado: (2014)

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis
por: de Groot, Karina A, et al.
Publicado: (2015)

Glucocorticoid Resistant Pediatric Acute Lymphoblastic Leukemia Samples Display Altered Splicing Profile and Vulnerability to Spliceosome Modulation
por: Sciarrillo, Rocco, et al.
Publicado: (2020)

Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells
por: Jansen, Gerrit, et al.
Publicado: (2023)

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia
por: van der Werf, Inge, et al.
Publicado: (2021)

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors
por: Verbrugge, Sue Ellen, et al.
Publicado: (2013)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
por: Zaal, Esther A., et al.
Publicado: (2017)

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2015)

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia
por: Cucchi, David G.J., et al.
Publicado: (2020)

Trimethylation of H3K27 during human cerebellar development in relation to medulloblastoma
por: Mir, Shahryar E., et al.
Publicado: (2017)

Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
por: Sciarrillo, Rocco, et al.
Publicado: (2018)

Proteasome inhibitors as experimental therapeutics of autoimmune diseases
por: Verbrugge, Sue Ellen, et al.
Publicado: (2015)

Dysregulation of the (immuno)proteasome pathway in malformations of cortical development
por: van Scheppingen, J., et al.
Publicado: (2016)

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
por: Cloos, Jacqueline, et al.
Publicado: (2018)

Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia
por: Zeijlemaker, Wendelien, et al.
Publicado: (2019)

MicroRNA-106b~25 cluster is upregulated in relapsed MLL-rearranged pediatric acute myeloid leukemia
por: Verboon, Lonneke J., et al.
Publicado: (2016)

Immuno- and Constitutive Proteasomes Do Not Differ in Their Abilities to Degrade Ubiquitinated Proteins
por: Nathan, James A., et al.
Publicado: (2013)

A Sentinel in the Crosstalk Between the Nervous and Immune System: The (Immuno)-Proteasome
por: Limanaqi, Fiona, et al.
Publicado: (2019)

Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors
por: Schiffrer, Eva Shannon, et al.
Publicado: (2021)

The Molecular Mechanisms Governing the Assembly of the Immuno- and Thymoproteasomes in the Presence of Constitutive Proteasomes
por: Watanabe, Ayaka, et al.
Publicado: (2022)

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide
por: Oerlemans, Ruud, et al.
Publicado: (2018)

Detection and targeting of splicing deregulation in pediatric acute myeloid leukemia stem cells
por: van der Werf, Inge, et al.
Publicado: (2023)

Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory study
por: van Litsenburg, Raphaële RL, et al.
Publicado: (2011)

Fragment-Sized and Bidentate (Immuno)Proteasome Inhibitors Derived from Cysteine and Threonine Targeting Warheads
por: Kollár, Levente, et al.
Publicado: (2021)

The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia
por: Urabe, Akiko, et al.
Publicado: (2023)

Targeting Progranulin as an Immuno-Neurology Therapeutic Approach
por: Boylan, Maria A., et al.
Publicado: (2023)

PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation
por: van Vuurden, Dannis G., et al.
Publicado: (2011)

Quantitative time-resolved analysis reveals intricate, differential regulation of standard- and immuno-proteasomes
por: Liepe, Juliane, et al.
Publicado: (2015)

Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes
por: Villoutreix, Bruno O., et al.
Publicado: (2017)

Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication
por: Hansen, Quinty, et al.
Publicado: (2022)

A chemical screen for medulloblastoma identifies quercetin as a putative radiosensitizer
por: Lagerweij, Tonny, et al.
Publicado: (2016)

Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome
por: Qin, Xianyun, et al.
Publicado: (2021)

Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno‐microenvironment in multiple myeloma
por: Barbato, Alessandro, et al.
Publicado: (2023)

Profile: ImmunoCellular Therapeutics Ltd.
por: Yu, John S.
Publicado: (2012)

An efficient method for the transduction of primary pediatric glioma neurospheres
por: Meel, Michaël H., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9auf97famklujrf2v244cmcri9